Lecture | October 3 | 6-7:30 p.m. | TBA
Ankit Mahadevia, Spero Therapeutics
Ankit Mahadevia, MD is CEO of Spero Therapeutics, a company that is dedicated to bring novel, life improving therapies to patients suffering from multidrug-resistant infections. He will discuss topics that are unique to the antibiotic field and the importance of bringing new therapies to patients while also speaking to the lessons learned from taking companies from development stage to the public arena.
Ankit Mahadevia is the CEO of Spero Therapeutics and a member of the Board of Directors. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, MA. In that capacity he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, three of which he led as Acting CEO. Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics. He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS).